open access
Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system
open access
Abstract
Background: Mitral regurgitation (MR) is one of the most common valvular diseases. Percutaneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on circulating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated.
Methods: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zurich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3–6 months.
Results: Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596–5,722) to 2,739 (IQR 1,440–4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days.
Conclusions: Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.
Abstract
Background: Mitral regurgitation (MR) is one of the most common valvular diseases. Percutaneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on circulating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated.
Methods: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zurich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3–6 months.
Results: Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596–5,722) to 2,739 (IQR 1,440–4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days.
Conclusions: Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.
Keywords
MitraClip, mitral regurgitation, percutaneous mitral valve repair, serum biomarkers, NT-proBNP
About this articleTitle
Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system
Journal
Issue
Pages
384-392
Published online
2016-06-10
Page views
1652
Article views/downloads
1436
DOI
10.5603/CJ.a2016.0024
Pubmed
Bibliographic record
Cardiol J 2016;23(4):384-392.
Keywords
MitraClip
mitral regurgitation
percutaneous mitral valve repair
serum biomarkers
NT-proBNP
Authors
Ji-Na Yoon
Antonio H. Frangieh
Adrian Attinger-Toller
Christiane Gruner
Felix C. Tanner
Maurizio Taramasso
Roberto Corti
Thomas F. Lüscher
Frank Ruschitzka
Dominique Bettex
Francesco Maisano
Oliver Gaemperli
